缺血性心室功能障碍血运重建或药物治疗的存活心肌与结局:REVIVED-BCIS2预设二次分析
REVIVED-BCIS2预设二次分析纳入610例LVEF≤35%的缺血性心肌病患者,评估存活与非存活心肌范围对PCI疗效及预后的影响。结果显示存活心肌范围与PCI疗效无交互作用,非存活心肌范围与主要终点相关,存活心肌范围与终点无关。
要点
- 存活心肌范围不识别可从PCI获益的缺血性心肌病患者。
- 非存活心肌范围与主要终点、全因死亡、心血管死亡及LV功能改善相关。
- 存活心肌范围与主要或次要终点均无关。
核心结论
- 存活心肌检测不能识别从PCI获益的缺血性心肌病患者。
- 非存活心肌范围而非存活心肌范围与无事件生存及左室功能改善可能性相关。
研究设计与样本
- 前瞻性开放标签随机临床试验,2013年8月28日至2020年3月19日招募,中位随访3.4年(IQR 2.3-5.0年)。
- 英国40个二级和三级中心,700例随机患者中纳入610例LVEF≤35%、广泛冠心病、至少4个静息功能障碍心肌节段有存活证据且接受盲法核心实验室存活特征分析者。
- 干预为经皮冠状动脉介入治疗(PCI)加最佳药物治疗。
主要发现
- PCI组主要终点发生107/295例,最佳药物治疗组114/315例。
- 存活或非存活心肌范围与PCI对主要或任何次要终点的效应无交互作用。
- 存活心肌范围与主要终点无关(每增加10%风险比0.98;95%CI 0.93-1.04)或任何次要终点。
- 非存活心肌范围与主要终点相关(风险比1.07;95%CI 1.00-1.15)、全因死亡、心血管死亡及左室功能改善。
关键数值与推荐
- 纳入标准:LVEF≤35%、广泛冠心病、至少4个静息功能障碍心肌节段有存活证据。
- 主要终点:全因死亡或心力衰竭住院的复合终点。
- 次要终点:全因死亡、心血管死亡、心力衰竭住院及6个月左室功能改善。
临床怎么用
- 对于LVEF≤35%的缺血性心肌病患者,存活心肌检测不应作为选择PCI的依据。
- 非存活心肌范围较大提示事件风险较高且左室功能改善可能性较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In the Revascularization for Ischemic Ventricular Dysfunction (REVIVED-BCIS2) trial, percutaneous coronary intervention (PCI) did not improve outcomes for patients with ischemic left ventricular dysfunction. Whether myocardial viability testing had prognostic utility for these patients or identified a subpopulation who may benefit from PCI remained unclear. OBJECTIVE: To determine the effect of the extent of viable and nonviable myocardium on the effectiveness of PCI, prognosis, and improvement in left ventricular function. DESIGN, SETTING, AND PARTICIPANTS: Prospective open-label randomized clinical trial recruiting between August 28, 2013, and March 19, 2020, with a median follow-up of 3.4 years (IQR, 2.3-5.0 years). A total of 40 secondary and tertiary care centers in the United Kingdom were included. Of 700 randomly assigned patients, 610 with left ventricular ejection fraction less than or equal to 35%, extensive coronary artery disease, and evidence of viability in at least 4 myocardial segments that were dysfunctional at rest and who underwent blinded core laboratory viability characterization were included. Data analysis was conducted from March 31, 2022, to May 1, 2023. INTERVENTION: Percutaneous coronary intervention in addition to optimal medical therapy. MAIN OUTCOMES AND MEASURES: Blinded core laboratory analysis was performed of cardiac magnetic resonance imaging scans and dobutamine stress echocardiograms to quantify the extent of viable and nonviable myocardium, expressed as an absolute percentage of left ventricular mass. The primary outcome of this subgroup analysis was the composite of all-cause death or hospitalization for heart failure. Secondary outcomes were all-cause death, cardiovascular death, hospitalization for heart failure, and improved left ventricular function at 6 months. RESULTS: The mean (SD) age of the participants was 69.3 (9.0) years. In the PCI group, 258 (87%) were male, and in the optimal medical therapy group, 277 (88%) were male. The primary outcome occurred in 107 of 295 participants assigned to PCI and 114 of 315 participants assigned to optimal medical therapy alone. There was no interaction between the extent of viable or nonviable myocardium and the effect of PCI on the primary or any secondary outcome. Across the study population, the extent of viable myocardium was not associated with the primary outcome (hazard ratio per 10% increase, 0.98; 95% CI, 0.93-1.04) or any secondary outcome. The extent of nonviable myocardium was associated with the primary outcome (hazard ratio, 1.07; 95% CI, 1.00-1.15), all-cause death, cardiovascular death, and improvement in left ventricular function. CONCLUSIONS AND RELEVANCE: This study found that viability testing does not identify patients with ischemic cardiomyopathy who benefit from PCI. The extent of nonviable myocardium, but not the extent of viable myocardium, is associated with event-free survival and likelihood of improvement of left ventricular function. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01920048.
引用
- Perera D, Ryan M, Morgan HP, et al. Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction: A Prespecified Secondary Analysis of the REVIVED-BCIS2 Trial. JAMA Cardiol. 2023. PMID: 37878295. doi:10.1001/jamacardio.2023.3803
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。